Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats

Clinical and Experimental Hypertension

Volumn 32, Issue 8, 2010, Pages 547-554

  Xie, Liangdi ^a,b   Lin, Peisen ^b   Xie, Hong ^a   Xu, Changsheng ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

atorvastatin; calcium regulating channels; losartan; pulmonary arterial hypertension; remodeling

Indexed keywords

ATORVASTATIN; INOSITOL 1,4,5 TRISPHOSPHATE RECEPTOR; LOSARTAN; MESSENGER RNA; MONOCROTALINE; PROTEIN; RYANODINE RECEPTOR 3; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE WALL; HEMODYNAMIC PARAMETERS; LUNG ARTERY PRESSURE; MALE; MEAN PULMONARY ARTERY PRESSURE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SPRAGUE DAWLEY RAT; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ARTERIOLES; BASE SEQUENCE; CALCIUM CHANNELS, L-TYPE; DISEASE MODELS, ANIMAL; DNA PRIMERS; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PULMONARY; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; LOSARTAN; MALE; MONOCROTALINE; PULMONARY ARTERY; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 79251472161     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2010.503295     Document Type: Article

References (25)

1. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, Hansen LA, Park K, Friedman PJ. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension: a morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-1586.
2. Strauss BH, Rabinovitch M. Adventitial fibroblasts: defining a role in vessel wall remodeling. Am J Respir Cell Mol Biol 2000;22:1-3.
3. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-285.
4. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000;47:648-657.
5. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.
6. Kip1. J Biol Chem 1999;274:21926-21931.
7. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stinqone AM, Chieffo A, Capozzolo C, Chiariello M. Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol. 2000;35:214-221.
8. Xie L, Lin Z, Sun M, Zhou H, Wu K, Li G. Inhibitory effect of fluvastatin on the proliferation of vascular smooth muscle cells in spontaneously hypertensive rats. Chinese Journal of Pathophysiology 2002;18:483-485.
9. Lin Z, Xie L, Wu K, Xu C, Wang H. Inhibitory effect of fluvastatin on the myocardial fibrosis in spontaneously hypertensive rats. Natl Med J China 2000;80:718-719.
10. Lin Z, Xie L, Wu K, Wang H, Xu C. Effects of fluvastatin on structure and function of resistant vessels in spontaneously hypertensive rats. Acta Pharmacologica Sinica 1999;20:855-860.
11. Xie L, Ouyang Q, Zhao H, Xie H, Zhang G. Effect of Benazepril and Fluvastatin on L-type Calcium Channel a1C Expression in Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats. Chin J Hypertension 2008;16:1100-1104.
12. Yang Y, Wu X, Chen J, Xie L. Effects of fluvastatin on endothelium dependent vasodilatation function in elder hypertensives. Chinese General Practice 2003;6:32-34.
13. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403-1408.
14. Kjeldsen SE, Devereux RB, Hille DA, Lyle PA, Dahlöf B, Julius S, Edelman JM, Snapinn SM, de Faire U, Fyhrquist F, Ibsen H, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study. Blood Press 2009;18:348-361.
15. Morrell NW, Higham MA, Phillips PG, Shakur BH, Robinson PJ, Beddoes RJ. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respir Res 2005;6:88.
16. Rondelet B, Kerbaul F, Van Beneden R, Hubloue I, Huez S, Fesler P, Remmelink M, Brimioulle S, Salmon I, Naeije R. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shuntinduced pulmonary hypertension. Am J Physiol Heart Circ Physiol 2005;289:H2319-H2324.
17. Aharinejad S, Schraufnagel DE, Böck P, MacKay CA, Larson EK, Miksovsky A, Marks SC Jr. Spontaneously hypertensive rats develop pulmonary hypertension and hypertrophy of pulmonary venous sphincters. Am J Pathol 1996;148:281-290.
18. Berridge MJ. Calcium signalling and cell proliferation. Bioessays 1995;17:491-500.
19. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano KI, Harada KI, Miyamoto S, Nakazawa H, Won KJ, Sato K. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997;49:157-230.
20. McDaniel SS, Platoshyn O, Wang J, Yu Y, Sweeney M, Krick S, Rubin LJ, Yuan JXJ. Capacitative Ca2+ entry in agonistinduced pulmonary vasoconstriction. Am J Physiol Lung Cell Mol Physiol. 2001;280:L870-L880.
21. Lin MJ, Leung GP, Zhang WM, Yang XR, Yip KP, Tse CM, Sham JS. Chronic hypoxia-induced upregulation of storeoperated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004;95:496-505.
22. Lin P, Xie X, Xie L, Xu C. Pulmonary arteriolar remodelling is prior to the increase in pulmonary arterial pressure in rats. Chin J Hypertension 2007;15:839-843.
23. Rakotoniaina Z, Guerard P, Lirussi F, Goirand F, Rochette L, Dumas M, Bardou M. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin. Naunyn Schmiedebergs Arch Pharmacol 2006;374:195-206.
24. Laudi S, Trump S, Schmitz V, West J, McMurtry IF, Mutlak H, Christians U, Weimann J, Kaisers U, Steudel. Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin. Am J Physiol Lung Cell Mol Physiol 2007;293:L630-L638.
25. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol 2007;293:L933-L940.